AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35754259 — intervention group
Group type: COMPARATOR
Intervention: Pain competence training (control group, n=255)
Number of subjects: 526
Study 33185932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isotretinoin (0.25 mg/kg/day) and five sessions of pulsed dye laser (PDL)
Number of subjects: 46
Study 33185932 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose isotretinoin (0.5 mg/kg/day)
Number of subjects: 46
Study 33185932 — intervention group
Group type: COMPARATOR
Intervention: ISO group (0.5 mg/kg/day)
Number of subjects: 46
Study 33185932 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO/PDL group (0.25 mg/kg/day + PDL)
Number of subjects: 46
Study 33185932 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO/PDL group
Number of subjects: 46
Study 35721734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy (Arm A)
Number of subjects: 62
Study 35721734 — intervention group
Group type: COMPARATOR
Intervention: Conservative approach (Arm B)
Number of subjects: 62
Study 34256668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilta-cel (ciltacabtagene autoleucel)
Number of subjects: 0
Study 34256668 — intervention group
Group type: COMPARATOR
Intervention: Ide-cel (idecabtagene vicleucel)
Number of subjects: 0
Study 35879941 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg GBP510 adjuvanted with AS03 (Group 1)
Number of subjects: 328
Study 35879941 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg unadjuvanted GBP510 (Group 2)
Number of subjects: 328
Study 35879941 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 µg GBP510 adjuvanted with AS03 (Group 3)
Number of subjects: 328
Study 35879941 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 µg unadjuvanted GBP510 (Group 4)
Number of subjects: 328
Study 35879941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 35879941 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg or 25 µg GBP510 adjuvanted with AS03
Number of subjects: 328
Study 33752636 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical, immunological and VL monitoring
Number of subjects: 142
Study 33752636 — intervention group
Group type: COMPARATOR
Intervention: Clinical and immunological monitoring (control)
Number of subjects: 142
Study 33752636 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of ART exposure
Number of subjects: 142
Study 33752636 — intervention group
Group type: EXPERIMENTAL
Intervention: Virologic failure
Number of subjects: 142
Study 32195934 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg at bedtime
Number of subjects: 26
Study 32195934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 616671307 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified MSLT performed at home
Number of subjects: 34
Study 616671307 — intervention group
Group type: COMPARATOR
Intervention: Modified MSLT performed in the hospital
Number of subjects: 34
Study 36127677 — intervention group
Group type: COMPARATOR
Intervention: exercise (physiotherapist‐prescribed exercise)
Number of subjects: 182
Study 36127677 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise plus app (physiotherapist‐prescribed exercise plus access to the ‘My Exercise Messages’ mobile app)
Number of subjects: 182
Study 36127677 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise plus app
Number of subjects: 182
Study 34001223 — intervention group
Group type: EXPERIMENTAL
Intervention: Credelio Plus tablets (milbemycin oxime + lotilaner)
Number of subjects: 395
Study 34001223 — intervention group
Group type: COMPARATOR
Intervention: Nexgard Spectra® tablets (control product)
Number of subjects: 395
Study 34001223 — intervention group
Group type: EXPERIMENTAL
Intervention: Credelio Plus tablets
Number of subjects: 395
Study 32936874 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrient supplement (3 sachets/d) enriched with l-arginine and omega-3 fatty acids
Number of subjects: 180
Study 32936874 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous control
Number of subjects: 180
Study 36188425 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax notoginseng Ejiao suppository
Number of subjects: 100
Study 36188425 — intervention group
Group type: COMPARATOR
Intervention: mesalazine suppository
Number of subjects: 100
Study 33164282 — intervention group
Group type: EXPERIMENTAL
Intervention: Children gaining social status on a simulated social media platform
Number of subjects: 123
Study 33164282 — intervention group
Group type: EXPERIMENTAL
Intervention: Children losing social status on a simulated social media platform
Number of subjects: 123
Study 33164282 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents observing their child's status gain
Number of subjects: 123
Study 33164282 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents observing their child's status loss
Number of subjects: 123
Study 33146324 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention strategy to promote walking
Number of subjects: 65
Study 33146324 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in primary health care
Number of subjects: 65
Study 35787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile oil (1.5 cc applied to lumbar region, three times a day for three weeks)
Number of subjects: 90
Study 35787809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (paraffin oil applied to lumbar region, three times a day for three weeks)
Number of subjects: 90
Study 35787809 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 90
Study 33500355 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) combined with orteronel
Number of subjects: 523
Study 33500355 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) combined with bicalutamide
Number of subjects: 523
Study 35914345 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation gamification program using immersive virtual reality
Number of subjects: 83
Study 35914345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity neonatal resuscitation simulations and online neonatal resuscitation program lectures
Number of subjects: 83
Study 35914345 — intervention group
Group type: COMPARATOR
Intervention: Online neonatal resuscitation program lectures
Number of subjects: 83
Study 33409919 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and selenium co-supplementation (8 × 10^9 CFU/day probiotic plus 200 μg/day selenium)
Number of subjects: 60
Study 33409919 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and selenium co-supplementation
Number of subjects: 60
Study 33409919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35444528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 81
Study 35444528 — intervention group
Group type: COMPARATOR
Intervention: Non-preparation group
Number of subjects: 81
Study 35444528 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota composition
Number of subjects: 81
Study 35444528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroides and Veillonella (genus)
Number of subjects: 81
Study 35444528 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsenella (genus)
Number of subjects: 81
Study 32678530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg once daily for up to 10 days)
Number of subjects: 6425
Study 32678530 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6425
Study 32077229 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction‐evacuation nephrostomy sheath (SENS)
Number of subjects: 60
Study 32077229 — intervention group
Group type: COMPARATOR
Intervention: Conventional nephrostomy sheath (NS)
Number of subjects: 60
Study 32134283 — intervention group
Group type: EXPERIMENTAL
Intervention: Online personalized feedback intervention (PFI)
Number of subjects: 204
Study 32134283 — intervention group
Group type: COMPARATOR
Intervention: Personalized normative feedback (PNF)
Number of subjects: 204
Study 32128869 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visit
Number of subjects: 651
Study 33451891 — intervention group
Group type: EXPERIMENTAL
Intervention: Head lift exercises (Shaker's exercise) performed three times a day for 8 weeks
Number of subjects: 50
Study 33451891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 32712944 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography (ICGA)
Number of subjects: 12
Study 32712944 — intervention group
Group type: COMPARATOR
Intervention: Color duplex ultrasonography (CDU)
Number of subjects: 12
Study 32712944 — intervention group
Group type: COMPARATOR
Intervention: Hand-held Doppler (hhD)
Number of subjects: 12
Study 35635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 3
Study 35635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Number of subjects: 3
Study 35635335 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 3
Study 33865349 — intervention group
Group type: EXPERIMENTAL
Intervention: Judo4Balance exercise programme (10 weeks)
Number of subjects: 142
Study 33865349 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 142
Study 32393728 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120
Study 32393728 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study 36199084 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on Health Belief Model (HBM) consisting of 6 virtual training sessions of 40-50 min and 2 follow-up sessions
Number of subjects: 150
Study 36199084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 36199084 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on Health Belief Model (HBM)
Number of subjects: 150
Study 33065768 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical cannabis treatment
Number of subjects: 1045
Study 36041869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP control (mean SBP 129.7 mmHg)
Number of subjects: 164
Study 36041869 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP control (mean SBP 138.3 mmHg)
Number of subjects: 164
Study 36041869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP control
Number of subjects: 164
Study 36041869 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP control
Number of subjects: 164
Study 34022580 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek version of the xerostomia questionnaire
Number of subjects: 72
Study 34251903 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (n=42)
Number of subjects: 181
Study 34251903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (n=52)
Number of subjects: 181
Study 34251903 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (n=87)
Number of subjects: 181
Study 34465368 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) led by a multidisciplinary team in the ED or Acute Medical Assessment Unit.
Number of subjects: 0
Study 34465368 — intervention group
Group type: COMPARATOR
Intervention: Usual patient care (Control group).
Number of subjects: 0
Study 34465368 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA (Intervention).
Number of subjects: 0
Study 32967912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T (administered as three infusions)
Number of subjects: 2
Study 32967912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T (first infusion)
Number of subjects: 2
Study 32967912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 2
Study 36258655 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 37
Study 36258655 — intervention group
Group type: COMPARATOR
Intervention: Presented Centered Therapy (PCT)
Number of subjects: 37
Study 36258655 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 37
Study 34533246 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtle fruit syrup with omeprazole
Number of subjects: 0
Study 34533246 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup with omeprazole
Number of subjects: 0
Study 35936952 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope with COVID-19 barrier box
Number of subjects: 33
Study 35936952 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope with COVID-19 barrier box
Number of subjects: 33
Study 35936952 — intervention group
Group type: COMPARATOR
Intervention: King Vision video laryngoscope without COVID-19 barrier box
Number of subjects: 33
Study 35936952 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope without COVID-19 barrier box
Number of subjects: 33
Study 35936952 — intervention group
Group type: EXPERIMENTAL
Intervention: Both laryngoscopes with COVID-19 barrier box
Number of subjects: 33
Study 35936952 — intervention group
Group type: COMPARATOR
Intervention: Both laryngoscopes without COVID-19 barrier box
Number of subjects: 33
Study 35257230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure therapy (8-min acupressure from Zhongwan (CV12), Guanyuan (CV4), and Tianshu (ST25) acupoints once a day for 4 weeks)
Number of subjects: 140
Study 35257230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure therapy
Number of subjects: 140
Study 32292469 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery ball combined with free position midwifery nursing
Number of subjects: 110
Study 32292469 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 110
Study 34982724 — intervention group
Group type: EXPERIMENTAL
Intervention: High engagement group (completed 74% of intervention items)
Number of subjects: 300
Study 34982724 — intervention group
Group type: COMPARATOR
Intervention: Low engagement group (completed 15% of intervention items)
Number of subjects: 300
Study 34687228 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) groups, 5 sessions of 2 hours each
Number of subjects: 85
Study 34687228 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 85
Study 32951538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Medical Management (IMM)
Number of subjects: 1618
Study 34085769 — intervention group
Group type: EXPERIMENTAL
Intervention: YH12852 (0.05-5 mg)
Number of subjects: 0
Study 34085769 — intervention group
Group type: EXPERIMENTAL
Intervention: YH12852 (0.05-0.1 mg)
Number of subjects: 0
Study 34085769 — intervention group
Group type: EXPERIMENTAL
Intervention: YH12852 (doses >0.1 mg extrapolated)
Number of subjects: 0
Study 34085769 — intervention group
Group type: COMPARATOR
Intervention: Gastric Emptying Breath Test (GEBT)
Number of subjects: 0
Study 32271184 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy (EAET)
Number of subjects: 196
Study 32271184 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 196
Study 32271184 — intervention group
Group type: COMPARATOR
Intervention: Education (Control)
Number of subjects: 196
Study 33405051 — intervention group
Group type: COMPARATOR
Intervention: G. lucidum treatment
Number of subjects: 120
Study 33256419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylera® (quadruple therapy)
Number of subjects: 108
Study 33256419 — intervention group
Group type: COMPARATOR
Intervention: AST-guided triple therapy
Number of subjects: 108
Study 33256419 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Pylera® and AST-guided triple therapy)
Number of subjects: 108
Study 36127718 — intervention group
Group type: EXPERIMENTAL
Intervention: SH2018-10 miniscrews (length 10 mm, ø 1.8-2.0 mm)
Number of subjects: 92
Study 36127718 — intervention group
Group type: COMPARATOR
Intervention: SH1514-08 miniscrews (length 8 mm, ø 1.4-1.5 mm)
Number of subjects: 92
Study 36127718 — intervention group
Group type: EXPERIMENTAL
Intervention: SH2018-10 miniscrews
Number of subjects: 92
Study 36127718 — intervention group
Group type: COMPARATOR
Intervention: SH1514-08 miniscrews
Number of subjects: 92
Study 33709870 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message fit with promotion focus
Number of subjects: 0
Study 33709870 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message nonfit with prevention focus
Number of subjects: 0
Study 32719981 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (ELD) 0.75 μg once-a-day for 24 weeks
Number of subjects: 124
Study 32719981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 35 mg once-a-week for 24 weeks
Number of subjects: 124
Study 32719981 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (ELD)
Number of subjects: 124
Study 32719981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Number of subjects: 124
Study 32719981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ELD and ALN
Number of subjects: 124
Study 36064325 — intervention group
Group type: EXPERIMENTAL
Intervention: NER1006 (1 L polyethylene glycol-based preparation)
Number of subjects: 214
Study 33788465 — intervention group
Group type: EXPERIMENTAL
Intervention: Wei's triple nine needling combined with conventional medication
Number of subjects: 90
Study 33788465 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication
Number of subjects: 90
Study 36429402 — intervention group
Group type: EXPERIMENTAL
Intervention: ad hoc mobile app and health data measuring devices
Number of subjects: 70
Study 33222703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 0
Study 33222703 — intervention group
Group type: COMPARATOR
Intervention: Inactive control therapy (befriending)
Number of subjects: 0
Study 35361653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (aerobic and resistance) + cognitive training (NEUROPEAK)
Number of subjects: 0
Study 35361653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise + control cognitive training (web searching)
Number of subjects: 0
Study 35361653 — intervention group
Group type: EXPERIMENTAL
Intervention: Control exercise (balance and toning) + cognitive training
Number of subjects: 0
Study 35361653 — intervention group
Group type: EXPERIMENTAL
Intervention: Control exercise + control cognitive training
Number of subjects: 0
Study 35361653 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the interventions
Number of subjects: 0
Study 35361653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-allocation preference for a given intervention
Number of subjects: 0
Study 35361653 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual and combined interventions
Number of subjects: 0
Study 34144176 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose HPV vaccination
Number of subjects: 0
Study 34144176 — intervention group
Group type: COMPARATOR
Intervention: Two-dose HPV vaccination
Number of subjects: 0
Study 32792427 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 60
Study 32792427 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 60
Study 33942397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarcane bagasse treated with Lactobacillus casei TH14, cellulase and molasses (BG)
Number of subjects: 8
Study 33942397 — intervention group
Group type: COMPARATOR
Intervention: Rice straw (RS)
Number of subjects: 8
Study 33305643 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular electrodes
Number of subjects: 24
Study 33305643 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular electrodes
Number of subjects: 24
Study 33305643 — intervention group
Group type: EXPERIMENTAL
Intervention: Right DLPFC tDCS
Number of subjects: 24
Study 33305643 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 24
Study 33305643 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 35267477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab monotherapy at 8 mg/kg Q2W
Number of subjects: 409
Study 35267477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab monotherapy at 12 mg/kg Q2W
Number of subjects: 409
Study 35267477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab monotherapy at 6 mg/kg QW
Number of subjects: 409
Study 35267477 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (12 mg/kg-Q2W)
Number of subjects: 409
Study 35267477 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (8 mg/kg-Q2W)
Number of subjects: 409
Study 35267477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 32488687 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check‐Up 4 Health (FCU4Health)
Number of subjects: 141
Study 32037592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-guided incremental optimization strategy
Number of subjects: 260
Study 32037592 — intervention group
Group type: COMPARATOR
Intervention: Blinded post-PCI coronary physiology measurements
Number of subjects: 260
Study 36217451 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal (TP) imaging-targeted biopsies
Number of subjects: 0
Study 36217451 — intervention group
Group type: COMPARATOR
Intervention: Transrectal (TR) imaging-targeted biopsies
Number of subjects: 0
Study 32200381 — intervention group
Group type: EXPERIMENTAL
Intervention: Community weight loss programme
Number of subjects: 73
Study 32200381 — intervention group
Group type: COMPARATOR
Intervention: Usual weight loss advice from a practice nurse
Number of subjects: 73
Study 32200381 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 73
Study 32200381 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% weight loss
Number of subjects: 73
Study 33853868 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual learning collaboratives
Number of subjects: 45
Study 33853868 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 45
Study 33433318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol 510 mg once or twice quarterly
Number of subjects: 173